Alimera’s Q3-2017 Revenues Increased 18 Percent; Company Sees Expanded Market for Iluvien

November 10, 2017: By Jon Swedien

alimera-sciencesAlimera Sciences posted Q3-2017 net revenues of $9.8 million, an 18 percent increase compared with Q3-2016, the company reported Nov. 1.

The Alpharetta, Georgia-based company markets Iluvien (fluocinolone acetonide intravitreal implant) 0.19 mg for the treatment of diabetic macular edema (DME).

Iluvien is the first DME treatment to deliver 36 months of continuous, low-dose corticosteroid with a single injection, Alimera said. It received US approval in September 2014 and is also available in 17 other countries.

Alimera CEO Dan Myers told investors in a conference call Nov. 2 that the company’s sales force was using study data to urge doctors to use Iluvien more frequently.

Typically, doctors have used Iluvien with patients who have not responded well to anti-VEGFs, Myers said. The study data, however, showed that Iluvien could lessen treatment burden for patients whose DME is well controlled by anti-VEGFs, Myers said.

The data he referred to showed that treatment with Iluvien lessened some patients’ need for anti-VEGF injections from once every 2.9 months to once every 22 months, Alimera said.

The study was conducted at four practices, involved more than 20 physicians, and included 130 patients (160 eyes), Myers said.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Bausch + Lomb Inks Deal with Express Scripts Expanding Vyzulta Coverage

Melgen Seeks Bond, Appeals Conviction on Charges of Medicare Fraud

Avedro, FDA Agree on Design, Size of First Pivotal Phase III Trial for Epi-on Cross-linking

Iridex Reports 2017 Revenues of $41.6 Million

Bar-Ilan University Announces Nano-Drop Candidate to Correct Refractive Error

Essex Bio-Technology Agrees to Invest $5 Million in MeiraGTx, Developer of Gene Therapies

Clearside Biomedical Announces $85 Million Public Offering

ViewPoint Raises $35 Million for Topical Treatment Candidate for Cataracts, Presbyopia

Okogen Raises $10 Million in Series A Round for Viral Conjunctivitis Candidate

SightLife Surgical Acquires KAMRA Corneal Inlay from AcuFocus

Major Leaguer Tommy Pham Plays Through Keratoconus

Glaukos Reports 2017 Net Sales of $159.3 Million

Imprimis Posts 2017 Revenues of $26.77 Million, a 34 Percent Increase

STAAR’s 2017 Net Sales Total $90.6 Million

US FDA Warns Consumers Not to Use Products from Cantrell Drug Company

IDx’ AI-Based Diagnostics System Meets Endpoints in Pivotal Trial for DR

Aerie Plans to Launch Rhopressa in Q2-2018, Expects 2018 Revenues of $20 Million to $30 Million

Valeant Reports 2017 Revenues of $8.72 Billion, a Decline of 10 Percent

Carl Zeiss Meditec Reports $359.7 Million in Revenues for First Quarter of FY2018, a 5.3 Percent Increase

Ophthotech Partners with UMass to Develop ‘Minigene’ Therapy for Retinal Disease

Coming soon

2018 IOL Report: A Global Market Analysis for 2017 to 2023